Scarica l'app Stockscreener
2.92
1.02%
-0.03
Pre-mercato:
2.86
-0.06
-2.05%
Immix Biopharma Inc Borsa (IMMX) Ultime notizie
What makes Immix Biopharma Inc. stock price move sharplyFast Growing Stocks - Newser
How Immix Biopharma Inc. stock performs during market volatilityBreakout Level Watch - Newser
Why Immix Biopharma Inc. stock attracts strong analyst attentionDouble Your Capital Alerts - Newser
ImmixBio reports no neurotoxicity in CAR-T therapy for AL amyloidosis - Investing.com Nigeria
Immix Biopharma Says NXC-201 Safety Profile Shows Absence of Neurotoxicity in Low-Volume Disease - MarketScreener
Immix Biopharma Announces Class-Leading Safety Profile, Allowing Potential Future Indication Expansion - MarketScreener
Immix Biopharma Reports Class-Leading Safety Profile for CAR-T NXC-201 in Low-Volume AL Amyloidosis, On Track for BLA Submission - Nasdaq
Revolutionary CAR-T Safety Data: IMMX Reports Zero Neurotoxicity in Rare Disease Treatment - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Stock Price Up 1.5% – Here’s Why - Defense World
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
Immix Biopharma stock advances as H.C. Wainwright reiterates Buy rating - Investing.com
Immix Biopharma Expands NEXICART-2 Trial Sites Nationwide, Progressing Towards Biologics License Application for Cell Therapy in AL Amyloidosis - Nasdaq
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis - GlobeNewswire
Breakthrough Cell Therapy for AL Amyloidosis Accelerates Toward FDA Approval with 18 Trial Sites - Stock Titan
Immix Biopharma (NASDAQ:IMMX) Upgraded by Wall Street Zen to Hold Rating - Defense World
Immix Biopharma Holds Annual Meeting, Elects Directors - TipRanks
Immix Biopharma CEO Rachman buys $4998 in shares - Investing.com
Jane Street Group LLC Invests $39,000 in Immix Biopharma, Inc. (NASDAQ:IMMX) - Defense World
H.C. Wainwright Reiterates Buy Rating on Immix Biopharma (IMMX) Following Promising Interim Results from NXC-201 Trial - MSN
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright - Defense World
Immix Biopharma Attends FDA CEO Forum in Washington DC - GlobeNewswire
ImmixBio Joins Elite Pharma Leaders at FDA Commissioner's Strategic Forum on Drug Development - Stock Titan
Immix Biopharma — ASCO/KOL event reaffirms NXC-201’s potential - Smartkarma
HC Wainwright Comments on Immix Biopharma Q1 Earnings - Defense World
Immix Biopharma (NASDAQ:IMMX) Receives Buy Rating from HC Wainwright - Defense World
Immix Biopharma (IMMX) Achieves Significant Clinical Milestone w - GuruFocus
immix biopharma enters at-the-market offering agreement - Investing.com Australia
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial By Investing.com - Investing.com South Africa
H.C. Wainwright reaffirms Immix Biopharma stock Buy rating after trial - Investing.com
Immix Biopharma’s NXC-201 Achieves 70% Complete Response Rate in AL Amyloidosis Trial - Insider Monkey
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC - GuruFocus
Immix Biopharma (IMMX) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | IMMX Stock News - GuruFocus
Immix Biopharma Announces Primary Endpoint Met in positive - GlobeNewswire
Immix Biopharma reports high response rate in AL Amyloidosis trial By Investing.com - Investing.com South Africa
Immix Biopharma stock soars to 52-week high of $2.99 By Investing.com - Investing.com South Africa
immix biopharma enters at-the-market offering agreement By Investing.com - Investing.com South Africa
Immix Biopharma's NXC-201 Trial Meets Primary Endpoint in AL Amyloidosis - MarketScreener
Immix Biopharma stock soars to 52-week high of $2.99 - Investing.com Australia
Immix Biopharma Enters At The Market Offering Agreement - TipRanks
Immix Biopharma reports high response rate in AL Amyloidosis trial - Investing.com
Immix Biopharma Reports 70% Complete Response Rate for NXC-201 in Phase 1/2 AL Amyloidosis Trial at ASCO 2025 - Nasdaq
0.64%
0.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):